Financial and economic costs of scaling up the provision of HAART to HIV-infected health care workers in KwaZulu-Natal
- PMID: 16532083
Financial and economic costs of scaling up the provision of HAART to HIV-infected health care workers in KwaZulu-Natal
Abstract
Objectives: To provide new information on the financial and economic costs of providing highly active antiretroviral therapy (HAART) to health care workers in public-sector hospital settings in KwaZulu-Natal.
Design: An Excel model was used to estimate the cost of providing HAART to health care workers at two state-subsidised hospitals in Durban. Staff members were interviewed and protocols reviewed to identify the time and resources used to provide HAART to health care workers. The cost of the programme was estimated for various patient numbers.
Results: The financial cost of treating a patient for a year ranged from R5697 to R8762 depending on the hospital and the number of patients treated. The economic cost of treating a patient for a year ranged from R6123 to R8893. These costs were shown to be robust to changes in key variables.
Conclusions: This study provides evidence on the cost of providing HAART to health care workers and suggests that this strategy could reduce absenteeism and alleviate future staff shortages at moderate cost to hospitals. This is crucial, given the impending human resources crisis in health care in South Africa and the growing burden of HIV/AIDS. These cost estimates should be good indicators of the costs of extending antiretroviral therapy to health care workers in public-sector hospitals in KwaZulu-Natal.
Similar articles
-
HAART for hospital health care workers--an innovative programme.S Afr Med J. 2004 Jun;94(6):423-7. S Afr Med J. 2004. PMID: 15250450 Review. No abstract available.
-
The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.AIDS. 2006 Apr 4;20(6):907-14. doi: 10.1097/01.aids.0000218556.36661.47. AIDS. 2006. PMID: 16549976
-
National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.S Afr Med J. 2000 Aug;90(8):794-8. S Afr Med J. 2000. PMID: 11022629
-
The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.CMAJ. 2003 Jul 22;169(2):106-10. CMAJ. 2003. PMID: 12874156 Free PMC article.
-
[Cost of HIV treatment in highly active antiretroviral therapy in Japan].Nihon Rinsho. 2002 Apr;60(4):813-6. Nihon Rinsho. 2002. PMID: 11968794 Review. Japanese.
Cited by
-
Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries.BMJ Open. 2014 Jun 26;4(6):e003987. doi: 10.1136/bmjopen-2013-003987. BMJ Open. 2014. PMID: 24969782 Free PMC article.
-
Evaluation of Dynabeads and Cytospheres compared with flow cytometry to enumerate CD4+ T cells in HIV-infected Ugandans on antiretroviral therapy.J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):297-303. doi: 10.1097/QAI.0b013e31817bbc3a. J Acquir Immune Defic Syndr. 2008. PMID: 18545154 Free PMC article.
-
Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries.Bull World Health Organ. 2014 Jul 1;92(7):499-511AD. doi: 10.2471/BLT.13.127639. Epub 2014 Apr 1. Bull World Health Organ. 2014. PMID: 25110375 Free PMC article.
-
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.PLoS One. 2012;7(4):e33672. doi: 10.1371/journal.pone.0033672. Epub 2012 Apr 24. PLoS One. 2012. PMID: 22545079 Free PMC article. Clinical Trial.
-
The cost of providing combined prevention and treatment services, including ART, to female sex workers in Burkina Faso.PLoS One. 2014 Jun 20;9(6):e100107. doi: 10.1371/journal.pone.0100107. eCollection 2014. PLoS One. 2014. PMID: 24950185 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical